Micrornas 33, 122, And 208: A Potential Novel Targets In The Treatment Of Obesity, Diabetes, And Heart-Related Diseases

Keywords

Diabetes; Fatty acid oxidation; Lipid metabolism; MED13; MicroRNAs; Obesity

Abstract

Despite decades of research, obesity and diabetes remain major health problems in the USA and worldwide. Among the many complications associated with diabetes is an increased risk of cardiovascular diseases, including myocardial infarction and heart failure. Recently, microRNAs have emerged as important players in heart disease and energy regulation. However, little work has investigated the role of microRNAs in cardiac energy regulation. Both human and animal studies have reported a significant increase in circulating free fatty acids and triacylglycerol, increased cardiac reliance on fatty acid oxidation, and subsequent decrease in glucose oxidation which all contributes to insulin resistance and lipotoxicity seen in obesity and diabetes. Importantly, MED13 was initially identified as a negative regulator of lipid accumulation in Drosophilia. Various metabolic genes were downregulated in MED13 transgenic heart, including sterol regulatory element-binding protein. Moreover, miR-33 and miR-122 have recently revealed as key regulators of lipid metabolism. In this review, we will focus on the role of microRNAs in regulation of cardiac and total body energy metabolism. We will also discuss the pharmacological and non-pharmacological interventions that target microRNAs for the treatment of obesity and diabetes.

Publication Date

5-1-2017

Publication Title

Journal of Physiology and Biochemistry

Volume

73

Issue

2

Number of Pages

307-314

Document Type

Article

Personal Identifier

scopus

DOI Link

https://doi.org/10.1007/s13105-016-0543-z

Socpus ID

85003848855 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/85003848855

This document is currently not available here.

Share

COinS